Raymond James Financial
GLSI icon

Raymond James Financial’s Greenwich LifeSciences GLSI Stock Holding History

Raymond James Financial’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Sell
9,137
-700
-7% -$17K ﹤0.01% 5011
2026
Q1 		$236K Buy
+9,837
New +$257K ﹤0.01% 4799
2025
Q3 		– Sell
-718
Closed -$6.51K – 5667
2025
Q2 		$6.51K Buy
+718
New +$6.83K ﹤0.01% 6081

Other funds holding GLSI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial's GLSI Position: Q2 2026 in Review

Raymond James Financial reduced its Greenwich LifeSciences (GLSI) stake by 7.1% in Q2 2026, selling an estimated $17K and leaving 9,137 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #5011.

Raymond James Financial first reported a position in GLSI in Q2 2025 and has held it in 3 quarters since. The position peaked at $236K in Q1 2026. 57 funds tracked by Wall St. Rank hold GLSI as of Q2 2026.

  • Raymond James Financial held 9,137 shares of Greenwich LifeSciences worth $214K as of Q2 2026.
  • Raymond James Financial sold 700 Greenwich LifeSciences shares in Q2 2026, an estimated $17K.
  • Greenwich LifeSciences made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5011 holding.
  • Raymond James Financial first reported a position in Greenwich LifeSciences in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's Greenwich LifeSciences position peaked at $236K in Q1 2026.
  • 57 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.